New Research: Menopause Hormone Therapy After 65

As we navigate the journey of menopause, understanding and advocating for our health becomes paramount. For many women, menopause hormone therapy (MHT) is a key part of managing this transition, offering relief from symptoms and protection against certain health risks. However, the conversation around the use of MHT beyond the age of 65 has been limited and fraught with uncertainties. A groundbreaking study has now shed light on this very topic, offering insights that empower us to make informed decisions about our health.

Study Insights: Beyond the Age of 65

The study, led by Seo H Baik, Fitsum Baye, and Clement J McDonald, analyzed health outcomes for women using MHT beyond the age of 65. This comprehensive research, published in the Journal of Menopause, delved into different types of estrogen/progestogen, routes of administration, and dosage strengths, focusing on their impact on health outcomes such as mortality, cancer, cardiovascular diseases, and dementia.

Key Findings: Hormone Therapy Benefits and Risks

The Power of Estrogen Monotherapy

The study's findings highlight significant benefits associated with estrogen monotherapy, including reduced risks of mortality, breast cancer, lung cancer, colorectal cancer, congestive heart failure, venous thromboembolism, atrial fibrillation, acute myocardial infarction, and dementia. These benefits underscore the importance of understanding the type of hormone therapy and its potential impact on our health.

The Complexity of Combo-Therapy

When it comes to combination therapy with estrogen and progestogen, the study reveals a nuanced picture. While there are increased risks, particularly with breast cancer, these can be mitigated by opting for lower doses and non-oral routes like transdermal or vaginal administration. This finding is crucial for women weighing the pros and cons of combination therapy.

Clarification: Progestin vs. Progesterone in MHT Choices

A vital point to note, and one that Fempower Health has consistently emphasized through conversations with experts like Dr. Jerilynn Prior, is the difference between progestin and progesterone. This distinction is often overlooked but is critical for making informed choices about MHT. Progestins are synthetic hormones, while progesterone is natural. The study's findings on the different health outcomes associated with these hormones further highlight the importance of this distinction.

Empowering Decisions: Personalized Menopause Health Care

This study not only provides valuable insights into the use of MHT beyond 65 but also reinforces the need for personalized healthcare. As we advocate for our health, it's essential to have open discussions with healthcare providers about the benefits and risks of different MHT options, considering our unique health profiles and preferences.

Final Thoughts: Advocacy in Women's Health and Menopause Management

The journey through menopause and beyond is deeply personal and complex. Armed with the latest research and an understanding of the nuances of hormone therapy, we can make choices that best support our health and well-being. Let's continue to advocate for ourselves, seeking out the information and support we need to navigate this chapter of our lives confidently and informed.

Remember, you are your best health advocate. Stay empowered, informed, and connected to your needs as you navigate the path of menopause hormone therapy, especially beyond the age of 65.

Source

Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause. 2024 Apr 9. doi: 10.1097/GME.0000000000002335. Epub ahead of print. PMID: 38595196.

Disclaimer

The information shared by Fempower Health is not medical advice but for informational purposes to enable you to have more effective conversations with your doctor.  Always talk to your doctor before making health-related decisions. Additionally, the views expressed by the Fempower Health podcast guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.